Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Go back to Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer| Pfizer Inc. (NYSE: PFE) | Delayed: 25.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $25.08 | 52 Week Low | $28.25 | |||
| Day High | $25.08 | P/E | 15.20 | |||
| Day Low | $25.08 | EPS | $1.65 | |||
| Volume | 113,640 | |||||
